Showing 731-740 of 9294 results for "".
Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/series/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.Understanding the Effect of Targeting IL-17A/F in Psoriatic Arthritis
https://practicaldermatology.com/programs/practical-dermatology-il-17-journal-club/understanding-the-effect-of-targeting-il-17af-in-psoriatic-arthritis/56663/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Naeim T. Issa, MD, PhD, FAAD, continue their discussion of the Mediterranean Journal of Rheumatology article “Emerging Targets in Psoriatic Arthritis: Dual IL-17A/F and Selective TYK2 Inhibition in a Clinical Perspective,” focusinFDA Approves Axillary Hyperhidrosis Treatment; Study Examines Biologic Outcomes in Psoriasis
https://practicaldermatology.com/series/dermwire-tv/fda-approves-axillary-hyperhidrosis-treatment-study-examines-biologic-outcomes-psoriasis/26562/In this week's DermwireTV, the FDA approves a first-of-its-kind gel for axillary hyperhidrosis; a new analysis examines how smoking, BMI, and age affect biologic outcomes in psoriasis; and the CEO of Aerolase joins us to discuss the latest trends in the aesthetic laser market.PDT in Action: New Options for Actinic Keratosis
https://practicaldermatology.com/series/pdt-in-practice/pdt-in-action-new-options-for-actinic-keratosis/20210/Dr. Joel L. Cohen, a board-certified dermatologist practicing in Denver, shares insights into the use of photodynamic therapy (PDT) in his practice and how PDT has impacted the options for the treatment of actinic keratosis.Psoriasis Challenges and Alopecia Areata Advances
https://practicaldermatology.com/programs/practical-dermatology/psoriasis-challenges-and-alopecia-areata-advances/39885/Mona Shahriari, MD, FAAD, talks about the challenges psoriasis poses in certain parts of the body such as the scalp and nails, plus Brittany Craiglow, MD, FAAD, joins Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, to discuss the latest advances in alopecia areata.New Analysis of Benzene Contamination in BPO Products
https://practicaldermatology.com/series/dermwire-tv/new-analysis-benzene-contamination-bpo-products/29074/In this week's DermwireTV, new data continues to raise concerns about benzene contamination in BPO products; the FDA expands the approved dosage for Ameluz for actinic keratosis (AK); and in our PA Perspectives segment, Andrew Mastro discusses how to approach a contract negotiation.Noah Worcester 2024: Dr. Bhatia on Actinic Keratosis
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-bhatia-actinic-keratosis/24585/Neal Bhatia, MD, FAAD, summarizes his lecture on actinic keratosis and photodynamic therapy at the 2024 Noah Worcester Dermatological Society meeting.DermWireTV: Birch Triterpenes Gel Gets FDA Approval for EB, VTE Risk is Lower in Patients with AD, and Are Topical Steroids Affecting Bone Health?
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-birch-triterpenes-t-gel-gets-fda-approval-for-eb-vte-risk-is-lower-in-patients-with-ad-and-are-topical-steroids-affecting-bone-health/20233/A birch bark extract topical from Chiesi Global Rare Diseases represents the latest in treatment approvals for epidermolysis bullosa. Patients with atopic dermatitis may have a decreased risk for developing venous thromboembolism. Commonly prescribed topical steroids may raise some patients' risk foASLMS New Beginnings Initiative
https://practicaldermatology.com/programs/practical-dermatology/aslms-new-beginnings-initiative/18188/In 2014, the American Society for Laser Medicine and Surgery started its New Beginnings initiative. Initially launched to benefit cancer survivors, ASLMS physicians volunteered to remove radiation tattoos pro bono. Recently, the ASLMS, under the leadership of its president Paul Friedman, MD, expande